At the beginning of the COVID-19 pandemic, patients with immune-mediated inflammatory
diseases were considered to be at high risk for SARS-CoV-2 infection and the development …

Background The risk of severe COVID-19 outcomes in people with immune-mediated
inflammatory diseases and on immune-modifying drugs might not be fully mediated by …

Vaccination is an important and effective tool to prevent infections in the general population,
as well as in patients with autoimmune and inflammatory rheumatic diseases. It has been …

Almost 1 year into the coronavirus disease 2019 (COVID-19) pandemic, and after more than
50 million cases and 1.35 million deaths globally, reports of the successful conclusion of …

Studies have revealed that patients with immunemediated inflammatory diseases, especially
those on immunomodulatory medication, have attenuated immunogenicity to COVID-19 …

Background Disease-specific studies have reported impaired humoral responses after
SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated …

With the COVID-19 pandemic, there has been great uncertainty about whether the virus
could exacerbate autoimmune diseases such as rheumatoid arthritis given that infection can …

Background Real-world evidence on the association between autoimmune inflammatory
rheumatic diseases, therapies related to these diseases, and COVID-19 outcomes are …

Objectives Successful vaccination is key to overcoming the COVID-19 pandemic.
Immunosuppressive medication is known to potentially compromise vaccination responses …

Comment www. thelancet. com/rheumatology Vol 4 February 2022 e81 p= 0· 039). The
neutralisation assay showed a moderate correlation (Pearson R 0· 35; p< 0· 001) with …